{"filings":[{"id":582476,"accession_number":"0001437749-26-018098","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2026-05-21T20:23:32+00:00","items":["8.01","9.01"],"status":"ready","headline":"Apyx Medical publishes clinical data showing 81.8% cellulite improvement with Avéli-Renuvion combination","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["22 patients received single-session treatment combining Avéli subcision and Renuvion helium plasma RF.","Up to 81.8% of patients showed improvement in cellulite appearance at 180 days post-treatment.","3D imaging confirmed measurable reductions in dimple volume, surface area, and depth.","Histological analysis in a subset showed increased collagen and elastin with progressive tissue remodeling.","Study published in Aesthetic Surgery Journal Open Forum; supports combined approach for cellulite and skin laxity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":77963,"accession_number":"0001437749-26-016885","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2026-05-14T12:05:35+00:00","items":["8.01","9.01"],"status":"ready","headline":"Renuvion + liposuction shows higher satisfaction, lower revision rates in 113-patient study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Patients with Renuvion reported higher satisfaction with excess skin: Body-Q score 87.8 vs 73.8 (p=0.03).","Abdominoplasty rate more than 50% lower in Renuvion group (30.0% vs 67.1%).","Revision rate significantly lower with Renuvion (12.0% vs 37.5%; p=0.038).","Complication rates similar between groups (2.5% vs 2.7%).","Study published in Plastic and Reconstructive Surgery - Global Open."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98475,"accession_number":"0001437749-26-016000","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2026-05-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Apyx Medical receives FDA clearance for power liposuction on AYON Body Contouring System","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Expanded FDA 510(k) clearance for AYON Body Contouring System to include power liposuction, a reciprocating cannula for efficient fat removal.","Power liposuction reduces surgeon effort and OR time; adds as second advanced liposuction modality on unified platform.","Company plans limited commercial launch with early adopters to refine training and customer experience before scaling.","CEO Charlie Goodwin says AYON becomes gold-standard system in surgical aesthetics with this clearance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98474,"accession_number":"0001437749-26-015352","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apyx Medical Q1 revenue $12.5M (+32% YoY); raises FY2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $12.5M, up 32% YoY; Surgical Aesthetics grew 36% to $10.7M.","Net loss narrowed to $2.1M ($0.05 loss per share) from $4.2M ($0.10 loss).","Adjusted EBITDA loss improved to $0.3M from $2.4M in prior year.","Raised FY2026 revenue guidance to $59M-$60M from prior $57.5M-$58.5M.","International sales strong, especially South Korea; Renuvion won NewBeauty award."],"consensus_eps_estimate":-0.1081,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":12490000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113968,"accession_number":"0001437749-26-007420","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apyx Medical Q4 revenue record $19.2M, net loss narrows; FY2026 guidance $57.5-58.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue record $19.2M, +34.7% YoY; Surgical Aesthetics +38.1% to $16.7M driven by AYON launch.","Q4 net loss narrowed to $1.3M ($0.03/sh) from $4.6M ($0.12/sh); Adjusted EBITDA $0.7M vs ($2.2M).","FY2025 total revenue $52.8M (+9.9% YoY); net loss $11.2M ($0.27/sh) vs $23.5M ($0.66/sh) in 2024.","FY2026 guidance: total revenue $57.5M-$58.5M; Surgical Aesthetics rev $53M-$54M; OEM rev ~$4.5M.","Submitted 510(k) for AYON power liposuction label expansion; clearance anticipated mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113967,"accession_number":"0001437749-26-001048","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apyx Medical reports preliminary Q4 revenue up ~34% YoY; Surgical Aesthetics up 38%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Q4 revenue expected $19.0-19.2M, up ~34% YoY; FY revenue $52.7-52.9M, up ~10%.","Surgical Aesthetics Q4 revenue $16.6-16.8M (+38% YoY); U.S. Surgical Aesthetics up ~51% on AYON launch.","OEM Q4 revenue $2.4M (+13% YoY); FY OEM revenue $7.5M (-21% YoY).","CEO cites AYON momentum and GLP-1-driven demand for loose skin procedures.","Full financial results to be reported in March 2026."],"consensus_eps_estimate":-0.0584,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":52844000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130378,"accession_number":"0001493152-25-027481","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Apyx Medical files Certificate of Amendment to delete Article EIGHTH from charter","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved the amendment at the August 7, 2025 annual meeting.","Certificate filed with Delaware Secretary of State on December 8, 2025.","Article EIGHTH replaced with 'intentionally omitted' — no substantive change to business.","Full terms of amendment incorporated by reference from June 25, 2025 proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130377,"accession_number":"0001493152-25-024279","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Apyx Medical prices $10M public offering of 2.76M shares at $3.62/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 2,762,431 shares priced at $3.62 per share, with gross proceeds ~$9.4M.","Underwriter granted 45-day option for up to 414,365 additional shares.","Lucid Capital Markets is sole book-runner; offering closed Nov 19, 2025.","Net proceeds for working capital, sales/marketing, capex, acquisitions, debt repayment.","Shares issued under effective S-3 shelf registration (File No. 333-268532)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130376,"accession_number":"0001437749-25-033456","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apyx Medical Q3 rev $12.9M (+12% YoY); net loss $2.0M; raises FY guidance to $50.5-52.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $12.9M (+12% YoY); Surgical Aesthetics $11.1M (+19% YoY).","Net loss attributable to stockholders $2.0M ($0.05/sh) vs $4.7M loss in Q3 2024.","Adjusted EBITDA loss improved 96% to $0.1M from $2.4M in Q3 2024.","FY2025 revenue guidance raised to $50.5-52.5M (prev $50-52M); Surgical Aesthetics segment guided at $43-45M.","Initiated full U.S. commercial launch of AYON Body Contouring System; submitted 510(k) for power liposuction label expansion."],"consensus_eps_estimate":-0.1046,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":33680000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146921,"accession_number":"0001641172-25-023451","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Apyx Medical annual meeting: directors elected, auditor ratified, say-on-pay approved, charter amended","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five director nominees elected with wide margins; broker non-votes ~6.8M.","RSM US LLP ratified as independent auditor for FY2025 with ~26M votes in favor.","Non-binding advisory vote on executive compensation approved (19.0M for, 0.2M against).","Frequency of advisory vote set to one year (9.2M one-year, 7.5M three-year).","Charter amendment to delete Article EIGHTH approved (19.0M for, 0.1M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146920,"accession_number":"0001437749-25-025417","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apyx Medical Q2 revenue $11.4M, net loss $3.8M; raises FY2025 revenue guidance to $50-52M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $11.4M vs $12.1M YoY; Advanced Energy flat at $9.7M, OEM down 28.5% to $1.7M.","Net loss attributable to stockholders $3.8M ($0.09/shr) vs $6.6M ($0.19/shr) YoY; adjusted EBITDA loss $2.0M vs $4.3M.","Soft launch of AYON Body Contouring System exceeding expectations; commercial launch planned September 2025.","Renuvion launched in China via partner GlamMoon; initial procedures completed with strong clinical interest.","FY2025 revenue guidance raised to $50-52M (from $47.6-49M); Advanced Energy guidance $42-44M."],"consensus_eps_estimate":-0.0952,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":20803000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165413,"accession_number":"0001437749-25-016259","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Apyx Medical receives FDA 510(k) clearance for AYON Body Contouring System","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["AYON is the first FDA-cleared all-in-one platform combining fat removal, contouring, tissue contraction, and electrosurgery.","Initial clearance covers Renuvion for lax skin, ultrasound liposuction, electrocoagulation; power liposuction submission planned later in 2025.","Commercial launch with key opinion leader surgeons in critical geographies expected in second half of 2025.","Company highlights >15 million GLP-1 drug users as a growth driver for body contouring procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165412,"accession_number":"0001437749-25-015231","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apyx Medical Q1 revenue $9.4M (-8% YoY), Advanced Energy +6%, net loss narrows to $4.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to stockholders $4.2M ($0.10/sh) vs $7.6M ($0.22/sh) prior year; adjusted EBITDA loss $2.4M vs $5.3M.","Advanced Energy revenue up 6% to $7.9M; OEM down 45% to $1.5M. Total revenue $9.4M vs $10.2M.","Reaffirmed FY2025 guidance: total revenue $47.6M-$49.0M, Advanced Energy $39.6M-$41.0M, OEM ~$8.0M.","Planned launch of AYON Body Contouring System in H2 2025 pending FDA clearance; 510(k) submitted Q1 2025.","Renuvion won 2025 NewBeauty Award for 'Best Minimally Invasive Skin Tightener'; Dolores Catania named Chief of Confidence."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":9430000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165411,"accession_number":"0001437749-25-013413","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Apyx Medical announces two peer-reviewed studies on Renuvion in body contouring showing safety and efficacy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First prospective RCT (Barone, 76 patients) shows Renuvion improves abdominal skin laxity and satisfaction scores vs lipoabdominoplasty alone.","Second retrospective study (Vanek, 77 patients) finds no significant increase in complications with Renuvion despite longer surgical times.","CEO cites >15M patients on GLP-1 drugs as growth driver; Renuvion is only FDA-cleared device for post-liposuction skin laxity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183068,"accession_number":"0001437749-25-007383","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apyx Medical Q4 2024 revenue $14.2M (down 3% YoY); net loss narrows to $4.6M; submits AYON 510(k) ahead of schedule","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $14.2M (-3% YoY); Advanced Energy flat at $12.1M. Full year revenue $48.1M (-8%).","Net loss Q4 $4.6M ($0.12 per share) vs $9.6M loss in Q4 2023; adjusted EBITDA loss $2.2M vs $4.7M.","Full year 2024 net loss $23.5M ($0.66 per share) vs $18.7M; adjusted EBITDA loss $14.3M vs $13.4M.","Submitted 510(k) for AYON Body Contouring System ~90 days early; planned launch back half 2025 pending clearance.","Cost restructuring: workforce reduced ~25%, annual savings ~$4.3M. 2025 guidance: revenue $47.6-49.0M, opEx <$40M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183067,"accession_number":"0001437749-25-003036","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Apyx Medical names Shawn Roman COO with $305,760 base salary, bonus target ≥50%","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Shawn Roman appointed COO effective Jan 28, 2025; base salary $305,760.52.","Target annual bonus not less than 50% of base salary under board-approved plan.","Eligible for equity awards as determined by Compensation Committee.","Severance includes 12 months base pay continuation and COBRA premiums if terminated without cause or for good reason.","12-month post-employment non-compete and non-solicitation covenants apply."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183066,"accession_number":"0001437749-25-000927","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apyx Medical prelim Q4 rev $14.1-14.3M; Advanced Energy up >25% QoQ","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Q4 revenue $14.1-14.3M, down ~3-4% YoY; Advanced Energy ~$12.0-12.2M (flat YoY).","Full-year 2024 revenue $48.0-48.2M, down 8% YoY; Advanced Energy down 11% to $38.5-38.7M.","OEM revenue Q4 $2.1M (-17% YoY); full-year $9.5M (+6% YoY).","New AYON Body Contouring System expected to launch H2 2025 pending FDA clearance.","CEO cites doubled U.S. generator unit sales in H2 vs H1 and GLP-1-driven demand for skin treatments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":48102000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183065,"accession_number":"0001437749-25-000375","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Apyx submits 510(k) for AYON Body Contouring System; ahead of schedule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Submitted 510(k) premarket notification to FDA for AYON Body Contouring System.","AYON integrates infiltration, dual aspiration, ultrasound liposuction, electrocoagulation, volume enhancement, Renuvion skin tightening.","Company plans a second 510(k) later in 2025 for power-assisted liposuction.","Submission completed ~90 days earlier than originally expected, per CEO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199643,"accession_number":"0001493152-24-044154","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["1.01","2.02","2.03","3.02","5.02","8.01","9.01"],"status":"ready","headline":"Apyx Medical Q3 revenue down 4% to $11.5M; cuts FY24 guidance; workforce –25%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $4.7M ($0.14/share) vs $4.6M YoY; adjusted EBITDA loss $2.4M.","Total revenue $11.5M (Advanced Energy -6% to $9.3M; OEM +3% to $2.2M).","FY24 revenue guidance cut to $46.6-47.6M from prior $50.6-52.1M; net loss expected ~$25M.","Raised ~$7M via registered direct offering of 3M shares + pre-funded warrants at $1.18/share.","Reduced U.S. workforce ~25% for ~$4.3M annual savings; three directors resigned; COO appointed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":33880000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215660,"accession_number":"0000719135-24-000042","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Apyx Medical annual meeting elects all eight director nominees and ratifies auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders elected all eight director nominees; votes in favor ranged from 13.2M to 14.1M.","Stavros G. Vizirgianakis received 14,111,703 votes in favor, 92,624 against.","Ratification of RSM US LLP as independent auditor for 2024 passed with 20,781,403 votes in favor.","Broker non-votes on director elections totaled 7,211,012; no broker non-votes on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215659,"accession_number":"0000719135-24-000036","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apyx Medical Q2 revenue falls 10% to $12.1M; net loss widens; updates FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $12.1M (-10% YoY); Advanced Energy -17% to $9.8M, OEM +29% to $2.4M.","Net loss $6.6M ($0.19/share) vs $1.0M loss in Q2 2023; prior year had $2.7M sale-leaseback gain.","Adjusted EBITDA loss $4.3M, up 166% from $1.6M loss in Q2 2023.","FY2024 revenue guidance narrowed to $50.6-52.1M (from $49.7-52.9M); net loss guided $23.5-24.5M (improved).","Stavros Vizirgianakis appointed Chairman effective May 7, 2024, succeeding retiring Andrew Makrides."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":22393000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235048,"accession_number":"0000719135-24-000024","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apyx Medical Q1 revenue $10.2M (-16% YoY); net loss $7.6M; Chairman retires","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $10.2M (-16% YoY); Advanced Energy $7.5M (-23%); OEM $2.8M (+14%).","Net loss $7.6M ($0.22/share) vs $3.5M ($0.10) loss a year ago; Adjusted EBITDA loss $5.3M vs $4.0M.","Reaffirms FY2024 guidance: revenue $49.7M-$52.9M; net loss expected $24.3M-$26.5M.","Chairman Andrew Makrides retires after 42 years; Stavros Vizirgianakis elected Chairman effective May 7, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":10244000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235047,"accession_number":"0000719135-24-000023","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Apyx Medical appoints Stavros Vizirgianakis as Chairman; founder Andrew Makrides retires after 40+ years","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrew Makrides retired as Chairman effective May 7, 2024, after serving since 1982.","Stavros Vizirgianakis appointed Chairman and director to fill vacancy; term expires at 2024 annual meeting.","Vizirgianakis is a former CEO of Misonix and current director of Xtant Medical and Medinotec.","Agreement includes standstill until 2025 annual meeting, limiting ownership to 9.9% and requiring vote with Board.","Board and Vizirgianakis will cooperate to identify an additional director within six months if he holds 5%+ shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252873,"accession_number":"0000719135-24-000013","cik":719135,"company_name":"Apyx Medical Corp","ticker":"APYX","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Apyx Medical Q4 revenue up 16% to $14.7M; net loss widens to $9.6M; FY2024 guidance implies potential revenue decline","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 Advanced Energy revenue $12.1M (+15% YoY); net loss $9.6M ($0.28/shr) vs $6.0M ($0.17) a year ago.","Full year 2023 total revenue $52.3M (+18%); net loss improved to $18.7M ($0.54/shr) from $23.2M ($0.67) in 2022.","FY2024 guidance: revenue $49.7M-$52.9M (down 5% to up 1%); net loss $24.3M-$26.5M, wider than 2023's $18.7M loss.","New $45M Perceptive credit facility closed Nov 2023; initial $37.5M funded, used to repay MidCap and $2.7M in fees.","Appointed Matthew Hill as CFO effective Dec 4, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":171683203.41025642,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}